NexImmune, Inc. (NEXI)
OTCMKTS · Delayed Price · Currency is USD
0.0002
0.00 (0.00%)
Jul 31, 2025, 8:00 PM EDT

NexImmune Company Description

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States.

It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform.

The company’s product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials.

It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors.

NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.

NexImmune, Inc.
CountryUnited States
Founded2011
IndustryBiotechnology
SectorHealthcare
Employees6
CEOCraig Jalbert

Contact Details

Address:
9119 Gaither Road
Gaithersburg, Delaware 20877
United States
Phone301 825 9810
Websiteneximmune.com

Stock Details

Ticker SymbolNEXI
ExchangeOTCMKTS
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
ISIN NumberUS65344D1090
SIC Code2836

Key Executives

NamePosition
John Trainer M.B.A.Consultant
Craig R. Jalbert CIRAPresident, Treasurer, CS, Principal Executive Officer, Financial Off, and Principal Accounting Off
Karen HaslbeckHead of Human Resources
Dr. Daniel P. BednarikSenior Vice President of Molecular Engineering and Protein Design
Dr. Robert Douglas Knight M.D.Chief Medical Officer
Chad RubinSenior Vice President of Corporate Affairs
Dr. Jack A. Ragheb M.D., Ph.D.Senior Vice President of Translational Science
Matthew SchillerHead of Business Development